New eczema pill shows promise in early trial
NCT ID NCT07297602
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tests an oral medication called roflumilast for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). Over 12 weeks, 36 participants will take a daily pill to see if it reduces skin symptoms like itching and rash. The goal is to find a new treatment option that is easy to take by mouth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mansoura University Hospital
RECRUITINGAl Mansurah, Dakahlia Governorate, 35511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.